TARGET for NSCLC: Genomic Pathways and Use of EGFR Therapies

Activity Info

The goal of this initiative is to increase clinicians’ knowledge and improve their competence in understanding the latest advances in targeting genomic pathways for the treatment of non-small cell lung cancer (NSCLC) through a review of the current and ongoing research/clinical trials focused on new and emerging EGFR-based therapies.
Email
Activity Name TARGET for NSCLC: The Advancing Research Into Genomic Pathways and Use of EGFR Therapies
Project Number 9089
Grant Supporter(s) This activity is supported by educational grants from AstraZeneca and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Therapeutic Area Oncology, Pulmonology
Target Audience Oncologists, Pulmonologists
Release Date
October 12, 2021
Expiration Date October 12, 2022
Faculty Renato G. Martins, MD, MPH
Chair of Hematology Oncology and Palliative Care
VCU Massey Cancer Center
Department of Internal Medicine
Virginia Commonwealth University School of Medicine
Richmond, Virginia

Jose M. Pacheco, MD
Assistant Professor, Medicine-Medical Oncology
Lung Cancer Clinic–Anschutz
University of Colorado Hospital (UCH)
Aurora, CO

Debora S. Bruno, MD, MS
Assistant Professor, Department of Medicine School of Medicine
Cancer Prevention Control & Population Research Program
Case Comprehensive Cancer Center
Cleveland, OH

Program Goal

The goal of this initiative is to increase clinicians’ knowledge and improve their competence in understanding the latest advances in targeting genomic pathways for the treatment of non-small cell lung cancer (NSCLC) through a review of the current and ongoing research/clinical trials focused on new and emerging EGFR-based therapies.

Target Audience

This program is designed to meet the educational needs of oncologists, physician assistants, nurse practitioners, nurses, and other health care professionals involved in the treatment and management of patients with NSCLC.

Learning Objectives

Following this activity, participants should be able to:

  • Review the importance of testing for genetic biomarkers in patients with NSCLC to assist in treatment decision-making
  • Discuss updated recommendations for use of drugs targeting EGFR+ mutations and evaluate potential applications of emerging therapies targeting EGFR+ mutations
  • Describe mechanisms of resistance in treatment of EGFR+ NSCLC and develop strategies to overcome resistance to EGFR+ therapies

Available Credit

1.00 AAPA Category 1 CME credit

1.00 AMA PRA Category 1 Credit

1.00 ANCC contact hours

1.00 Participation

 

Accreditation Information

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Physicians
NCCN designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 1.0 contact hour.

Physician Assistants
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

NCCN Medical Education Disclosure Policy

It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers, and anyone involved in the planning and delivery of NCCN continuing education activities disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates, and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.

Definitions

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Lead Faculty/Developers

Debora S. Bruno, MD, MS

Assistant Professor, Department of Medicine School of Medicine

Cancer Prevention Control & Population Research Program

Case Comprehensive Cancer Center

Cleveland, OH

Renato G. Martins, MD, MPH

Chair of Hematology Oncology and Palliative Care

VCU Massey Cancer Center

Department of Internal Medicine

Virginia Commonwealth University School of Medicine

Richmond, Virginia

Jose M. Pacheco, MD

Assistant Professor, Medicine-Medical Oncology

Lung Cancer Clinic–Anschutz

University of Colorado Hospital (UCH)

Aurora, CO

Faculty Disclosures–Content Creators

The faculty listed below have no relevant financial relationship(s) with ineligible companies to disclose:

Renato Martins, MD

The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Jose Pacheco, MD
AstraZeneca Pharmaceuticals LP: Scientific Advisor
Blueprint Medicines: Scientific Advisor
Checkmate Pharmaceuticals: Grant/Research Support
Daiichi-Sankyo Co.: Grant/Research Support
Gerson Lehrman Group, Inc.: Scientific Advisor
Janssen Phamaceutica Products, LP: Product/Speakers Bureau
Jiangsu Hengrui Pharmaceuticals: Scientific Advisor
Jazz Pharmaceuticals Inc.: Scientific Advisor
Novartis Pharmaceuticals Corporation: Scientific Advisor
Pfizer Inc.: Grant/Research Support; Scientific Advisor
Research America: Scientific Advisor
Takeda Pharmaceuticals North America, Inc.: Scientific Advisor

Debora Bruno, MD
AstraZeneca Pharmaceuticals LP: Grant/Research Support
Tempus Labs, Inc.: Consulting Fee

Staff Disclosures

None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients.

Supporter Recognition

This activity is supported by educational grants from AstraZeneca and Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC. This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Instructions for Claiming CME/CE credit

Requirements for Receiving CE Credit: You will be able to view/print your certificate online once all requirements have been met. Within 30 days of the activity, you must:

  • Complete the adaptive learning module *
  • Complete the evaluation

 * You will be able to proceed to the evaluation once you have completed the entire adaptive learning module. Your progress is displayed on the home screen after launching the module. Your progress will be saved, so you can start and resume the module as needed.

REQUIRED HARDWARE/SOFTWARE

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
  • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing

Tags

Pulmonary | Oncology | CME (AMA PRA Category 1 Credit) | 1.0 - 60 mins | Nurse | Nurse Practitioner | PILOTforPulmonary.org | Online | Physician Assistant | Non-Small Cell Lung Cancer (NSCLC) |